Recent court rulings are changing the rules for healthcare whistleblowers, particularly in cases involving “kickbacks”. If you’ve witnessed a system designed to “nudge” doctors toward certain expensive drugs or services, a major new legal decision from 2025—United States v. Regeneron Pharmaceuticals—may impact how those cases are handled.
What Happened in the Regeneron Case?
The government sued Regeneron, alleging they paid tens of millions of dollars to a foundation to cover patient co-pays for an expensive eye drug. The government argued this was an illegal “kickback” designed to “nudge” doctors into prescribing their drug over cheaper alternatives.
The First Circuit Court of Appeals recently ruled in favor of the company, setting a much higher bar for what counts as a “false claim”.
The New “But-For” Rule
The court decided that for a kickback to violate the False Claims Act, the government or a whistleblower must prove “but-for” causation.
- The Old Way: It used to be enough to show that a kickback “tainted” the doctor’s decision.
- The New Way: Now, you must prove that the doctor would not have prescribed that drug or service if the kickback hadn’t existed.
Basically, a stronger showing of evidence is needed to prove that, if not for the kickback, a doctor would not have prescribed that certain drug to their patients.
Why This Matters for Whistleblowers
This ruling makes it harder for regular employees to bring “qui tam” lawsuits based purely on illegal “nudges”. It is no longer enough to show that a company offered a financial incentive; you now must show that the incentive actually changed the medical outcome.
However, the court left one door open:
- False Certifications: Whistleblowers can still succeed if they can show that a company falsely lied about following the law to get paid by the government.
- No “But-For” Required: In these “false certification” cases, you may not have to meet that difficult “but-for” standard.
Key Takeaways: Navigating the New But-For Rule for WhistleblowersThe Bottom Line
The legal landscape is shifting. While the “but-for” rule creates a new barrier, whistleblowers remain the front line against healthcare fraud.
Do you have evidence of a company using secret incentives to “nudge” medical decisions? We can help you determine the best legal path forward in this changing environment.